Overview

Comparison of Inhaled Mannitol and rhDNase in Children With Cystic Fibrosis

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the medium term efficacy and safety profile of inhaled mannitol, on its own and also as an additional therapy to rhDNase (pulmozyme). In particular, we will assess the impact on: lung function; airway inflammation; sputum microbiology; exacerbations; quality of life; adverse events; exercise tolerance; total costs of hospital and community care; and cost-effectiveness.
Phase:
Phase 2
Details
Lead Sponsor:
Pharmaxis
Treatments:
Mannitol